ETN 003
Alternative Names: ETN-003Latest Information Update: 16 Sep 2021
At a glance
- Originator Shanghai ETERN Biopharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 06 Sep 2021 ETN 003 is available for licensing as of 06 Sep 2021. http://www.eterntx.com/?page_id=241
- 06 Sep 2021 Preclinical trials in Acute myeloid leukaemia in China (unspecified route) (Shanghai ETERN Biopharma pipeline, September 2021)
- 06 Sep 2021 Preclinical trials in Solid tumours in China (unspecified route) (Shanghai ETERN Biopharma pipeline, September 2021)